ID   TLK2_HUMAN              Reviewed;         772 AA.
AC   Q86UE8; Q9UKI7; Q9Y4F7;
DT   22-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   22-AUG-2003, sequence version 2.
DT   05-OCT-2010, entry version 88.
DE   RecName: Full=Serine/threonine-protein kinase tousled-like 2;
DE            EC=2.7.11.1;
DE   AltName: Full=PKU-alpha;
DE   AltName: Full=Tousled-like kinase 2;
GN   Name=TLK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), VARIANT ARG-6, FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta, and Testis;
RX   MEDLINE=98087437; PubMed=9427565; DOI=10.1016/S0378-1119(97)00495-2;
RA   Yamakawa A., Kameoka Y., Hashimoto K., Yoshitake Y., Nishikawa K.,
RA   Tanihara K., Date T.;
RT   "cDNA cloning and chromosomal mapping of genes encoding novel protein
RT   kinases termed PKU-alpha and PKU-beta, which have nuclear localization
RT   signal.";
RL   Gene 202:193-201(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, MUTAGENESIS OF
RP   ASP-613, SUBCELLULAR LOCATION, INTERACTION WITH TLK1, AND ENZYME
RP   REGULATION.
RC   TISSUE=Placenta;
RX   MEDLINE=99452775; PubMed=10523312; DOI=10.1093/emboj/18.20.5691;
RA   Sillje H.H.W., Takahashi K., Tanaka K., Van Houwe G., Nigg E.A.;
RT   "Mammalian homologues of the plant tousled gene code for cell-cycle-
RT   regulated kinases with maximal activities linked to ongoing DNA
RT   replication.";
RL   EMBO J. 18:5691-5702(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, INTERACTION WITH ASF1A AND ASF1B, AND MUTAGENESIS OF
RP   ASP-613.
RX   MEDLINE=21363240; PubMed=11470414; DOI=10.1016/S0960-9822(01)00298-6;
RA   Sillje H.H.W., Nigg E.A.;
RT   "Identification of human Asf1 chromatin assembly factors as substrates
RT   of Tousled-like kinases.";
RL   Curr. Biol. 11:1068-1073(2001).
RN   [5]
RP   FUNCTION, AND ENZYME REGULATION.
RX   MEDLINE=22546651; PubMed=12660173; DOI=10.1093/emboj/cdg151;
RA   Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J.,
RA   Hansen K.;
RT   "Human tousled like kinases are targeted by an ATM- and Chk1-dependent
RT   DNA damage checkpoint.";
RL   EMBO J. 22:1676-1687(2003).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99 AND SER-753, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99; SER-111; SER-115 AND
RP   SER-771, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32; TYR-70; THR-72;
RP   SER-73; SER-94; THR-98; SER-99; SER-110; SER-111; SER-115; SER-117;
RP   SER-134; SER-196; THR-300; SER-769; SER-770 AND SER-771, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-6; ASP-54; GLY-95; GLY-108;
RP   LEU-109; LEU-173 AND GLN-262.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Rapidly and transiently inhibited by phosphorylation
CC       following the generation of DNA double-stranded breaks during S-
CC       phase. This is cell cycle checkpoint and ATM-pathway dependent and
CC       appears to regulate processes involved in chromatin assembly.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Cell-cycle regulated, maximal activity in S-
CC       phase. Inactivated by phosphorylation at Ser-750, potentially by
CC       CHK1.
CC   -!- SUBUNIT: Heterodimerizes with TLK1. Interacts with ASF1A and
CC       ASF1B.
CC   -!- INTERACTION:
CC       Q9NVP2:ASF1B; NbExp=1; IntAct=EBI-1047967, EBI-1055650;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q86UE8-1; Sequence=Displayed;
CC         Note=No experimental confirmation available;
CC       Name=2;
CC         IsoId=Q86UE8-2; Sequence=VSP_050573;
CC       Name=3;
CC         IsoId=Q86UE8-3; Sequence=VSP_050572, VSP_050573;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Present in fetal placenta,
CC       liver, kidney, pancreas, heart and skeletal muscle. Also found in
CC       adult cell lines.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF03095.1; Type=Erroneous initiation;
CC       Sequence=AAH44925.2; Type=Erroneous initiation;
CC       Sequence=BAA20561.1; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB004884; BAA20561.1; ALT_INIT; mRNA.
DR   EMBL; AF162667; AAF03095.1; ALT_INIT; mRNA.
DR   EMBL; BC044925; AAH44925.2; ALT_INIT; mRNA.
DR   IPI; IPI00337659; -.
DR   IPI; IPI00337660; -.
DR   IPI; IPI00385652; -.
DR   RefSeq; NP_001106178.1; -.
DR   RefSeq; NP_006843.2; -.
DR   UniGene; Hs.445078; -.
DR   ProteinModelPortal; Q86UE8; -.
DR   SMR; Q86UE8; 456-741.
DR   IntAct; Q86UE8; 1.
DR   STRING; Q86UE8; -.
DR   PhosphoSite; Q86UE8; -.
DR   PRIDE; Q86UE8; -.
DR   Ensembl; ENST00000326270; ENSP00000316512; ENSG00000146872.
DR   GeneID; 11011; -.
DR   KEGG; hsa:11011; -.
DR   UCSC; uc002izz.2; human.
DR   UCSC; uc002jaa.2; human.
DR   UCSC; uc010ddp.1; human.
DR   CTD; 11011; -.
DR   GeneCards; GC17P060556; -.
DR   H-InvDB; HIX0027107; -.
DR   HGNC; HGNC:11842; TLK2.
DR   MIM; 608439; gene.
DR   PharmGKB; PA36544; -.
DR   eggNOG; prNOG06232; -.
DR   HOGENOM; HBG607699; -.
DR   HOVERGEN; HBG007938; -.
DR   InParanoid; Q86UE8; -.
DR   OMA; NEIRPPI; -.
DR   OrthoDB; EOG96HJW9; -.
DR   PhylomeDB; Q86UE8; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 41827; -.
DR   ArrayExpress; Q86UE8; -.
DR   Bgee; Q86UE8; -.
DR   CleanEx; HS_TLK2; -.
DR   Genevestigator; Q86UE8; -.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0016568; P:chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0023034; P:intracellular signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001672; P:regulation of chromatin assembly or disasse...; IDA:UniProtKB.
DR   GO; GO:0006974; P:response to DNA damage stimulus; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell cycle; Chromatin regulator;
KW   Coiled coil; Complete proteome; DNA damage; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    772       Serine/threonine-protein kinase tousled-
FT                                like 2.
FT                                /FTId=PRO_0000086754.
FT   DOMAIN      462    741       Protein kinase.
FT   NP_BIND     468    476       ATP (By similarity).
FT   COILED      225    276       Potential.
FT   COILED      317    347       Potential.
FT   COILED      403    451       Potential.
FT   ACT_SITE    592    592       Proton acceptor.
FT   BINDING     491    491       ATP (By similarity).
FT   MOD_RES      32     32       Phosphoserine.
FT   MOD_RES      70     70       Phosphotyrosine.
FT   MOD_RES      72     72       Phosphothreonine.
FT   MOD_RES      73     73       Phosphoserine.
FT   MOD_RES      94     94       Phosphoserine.
FT   MOD_RES      98     98       Phosphothreonine.
FT   MOD_RES      99     99       Phosphoserine.
FT   MOD_RES     110    110       Phosphoserine.
FT   MOD_RES     111    111       Phosphoserine.
FT   MOD_RES     115    115       Phosphoserine.
FT   MOD_RES     117    117       Phosphoserine.
FT   MOD_RES     134    134       Phosphoserine.
FT   MOD_RES     196    196       Phosphoserine.
FT   MOD_RES     300    300       Phosphothreonine.
FT   MOD_RES     750    750       Phosphoserine (By similarity).
FT   MOD_RES     753    753       Phosphoserine.
FT   MOD_RES     769    769       Phosphoserine.
FT   MOD_RES     770    770       Phosphoserine.
FT   MOD_RES     771    771       Phosphoserine.
FT   VAR_SEQ      90    121       Missing (in isoform 3).
FT                                /FTId=VSP_050572.
FT   VAR_SEQ     375    396       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_050573.
FT   VARIANT       6      6       H -> R (in dbSNP:rs45550140).
FT                                /FTId=VAR_041216.
FT   VARIANT      54     54       E -> D.
FT                                /FTId=VAR_041217.
FT   VARIANT      95     95       A -> G.
FT                                /FTId=VAR_041218.
FT   VARIANT     108    108       A -> G.
FT                                /FTId=VAR_041219.
FT   VARIANT     109    109       R -> L.
FT                                /FTId=VAR_041220.
FT   VARIANT     173    173       F -> L (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041221.
FT   VARIANT     262    262       R -> Q.
FT                                /FTId=VAR_041222.
FT   MUTAGEN     613    613       D->A: Loss of kinase activity.
FT   CONFLICT      1      1       M -> I (in Ref. 1; BAA20561).
FT   CONFLICT    161    161       T -> P (in Ref. 1; BAA20561).
FT   CONFLICT    207    207       Q -> R (in Ref. 2; AAF03095).
FT   CONFLICT    562    562       M -> I (in Ref. 1; BAA20561).
FT   CONFLICT    727    727       E -> R (in Ref. 2; AAF03095).
SQ   SEQUENCE   772 AA;  87661 MW;  765EE37ED4A4ADEC CRC64;
     MMEELHSLDP RRQELLEARF TGVGVSKGPL NSESSNQSLC SVGSLSDKEV ETPEKKQNDQ
     RNRKRKAEPY ETSQGKGTPR GHKISDYFEF AGGSAPGTSP GRSVPPVARS SPQHSLSNPL
     PRRVEQPLYG LDGSAAKEAT EEQSALPTLM SVMLAKPRLD TEQLAQRGAG LCFTFVSAQQ
     NSPSSTGSGN TEHSCSSQKQ ISIQHRQTQS DLTIEKISAL ENSKNSDLEK KEGRIDDLLR
     ANCDLRRQID EQQKMLEKYK ERLNRCVTMS KKLLIEKSKQ EKMACRDKSM QDRLRLGHFT
     TVRHGASFTE QWTDGYAFQN LIKQQERINS QREEIERQRK MLAKRKPPAM GQAPPATNEQ
     KQRKSKTNGA ENETPSSGNT ELKDTAPALG AHSLLRLTLA EYHEQEEIFK LRLGHLKKEE
     AEIQAELERL ERVRNLHIRE LKRIHNEDNS QFKDHPTLND RYLLLHLLGR GGFSEVYKAF
     DLTEQRYVAV KIHQLNKNWR DEKKENYHKH ACREYRIHKE LDHPRIVKLY DYFSLDTDSF
     CTVLEYCEGN DLDFYLKQHK LMSEKEARSI IMQIVNALKY LNEIKPPIIH YDLKPGNILL
     VNGTACGEIK ITDFGLSKIM DDDSYNSVDG MELTSQGAGT YWYLPPECFV VGKEPPKISN
     KVDVWSVGVI FYQCLYGRKP FGHNQSQQDI LQENTILKAT EVQFPPKPVV TPEAKAFIRR
     CLAYRKEDRI DVQQLACDPY LLPHIRKSVS TSSPAGAAIA STSGASNNSS SN
//
